Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder

Human Pathology

Volumn 41, Issue 4, 2010, Pages 485-492

  Shafizadeh, Nafis ^a   Grenert, James P ^a   Sahai, Vaibhav ^c   Kakar, Sanjay ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MERCY HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Cholangiocarcinoma; EGFR; FISH; HER 2 neu; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT ADENOCARCINOMA; CANCER GRADING; CANCER INVASION; CANCER SURVIVAL; CHROMOSOME 7; CHRONIC CHOLECYSTITIS; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GALLBLADDER ADENOCARCINOMA; GALLBLADDER CARCINOMA; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; GALLBLADDER NEOPLASMS; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 77649339494     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.10.002     Document Type: Article

References (50)

1. Hammill C.W., and Wong L.L. Intrahepatic cholangiocarcinoma: a malignancy of increasing importance. J Am Coll Surg 207 (2008) 594-603
2. Aljiffry M., Abdulelah A., Walsh M., Peltekian K., Alwayn I., and Molinari M. Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg 208 (2009) 134-147
3. Shaib Y., and El-Serag H.B. The epidemiology of cholangiocarcinoma. Semin Liver Dis 24 (2004) 115-125
4. Reid K.M., Ramos-De la Medina A., and Donohue J.H. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg 11 (2007) 671-681
5. Kelley S.T., Bloomston M., et al. Cholangiocarcinoma: advocate an aggressive approach with adjuvant chemotherapy. Am Surg 70 (2004) 743-748
6. Takada T., Amano H., Yasuda H., et al. Is post-operative chemotherapy useful for gallbladder carcinoma? A phase III multi-center prospective randomized controlled trial in patients with resectable pancreatobiliary carcinoma. Cancer 95 (2002) 1685-1695
7. Yoon J.H., Higuchi H., Werneburg N.W., Kaufmann S.H., and Gores G.J. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 122 (2002) 985-993
8. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20 18 Suppl (2002) 1S-13S
9. Calvo E., and Rowinsky E.K. Clinical experience with monoclonal antibodies to epidermal growth factor receptor. Curr Oncol Rep 7 (2005) 96-103
10. Argyriou A., and Kalofonos H.P. Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumours. Mol Med 15 (2009) 183-191
11. Capdevila J., Elez E., Macarulla T., Ramos F.J., Ruiz-Echarri M., and Tabernero J. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev 35 (2009) 354-363
12. Wiedmann M., Feisthammel J., Blüthner T., et al. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs 17 (2006) 783-795
13. Sprinzl M.F., Schimanski C.C., Moehler M., Schadmand-Fischer S., Galle P.R., and Kanzler S. Gemcitabine in combination with EGFR antibody (cetuximab) as a treatment of cholangiocarcinoma: a case report. BMC Cancer 6 (2006) 190
14. Paule B., Herelle M.O., Rage E., et al. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 72 (2007) 105-110
15. Huang T.W., Wang C.H., and Hsieh C.B. Effects of the anti-epidermal growth factor receptor cetuximab on cholangiocarcinoma of the liver. Onkologie 30 (2007) 129-131
16. Philip P.A., Mahoney M.R., Allmer C., et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24 (2006) 3069-3074
17. Leone F., Cavalloni G., Pignochino Y., et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res 12 (2006) 1680-1685
18. Nonomura A., Ohta G., Nakanuma Y., et al. Simultaneous detection of epidermal growth factor receptor, epidermal growth factor, and ras p21 in cholangiocarcinoma by an immunocytochemical method. Liver 3 (1998) 157-166
19. Ito Y., Takeda T., Sasaki Y., et al. Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract 197 (2001) 95-100
20. Altimari A., Fiorentino M., Gabusi E., et al. Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig Liver Dis 35 (2003) 332-338
21. Jan Y.Y., Yeh T.S., Yeh J.N., et al. Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma. Ann Surg 240 (2004) 89-94
22. Kim H.J., Kim J.S., Kang C.D., et al. Expression of epidermal growth factor receptor, ErbB2, and matrix metalloproteinase-9 in hepatolithiasis and cholangiocarcinoma. Korean J Gastro 45 (2005) 52-59
23. Nakazawa K., Dobashi Y., Suzuki S., et al. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 206 (2005) 356-365
24. Yoshikawa D., Ojima H., Iwasaki M., et al. Clinicopathologic and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98 (2008) 418-425
25. Kaufman M., Mehrotra B., Limaye S., et al. EGFR expression in gallbladder carcinoma in North America. Int J Med Sci 5 (2008) 285-291
26. Ukita Y., Kato M., and Terada T. Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. J Hepatol 36 (2002) 780-785
27. Settakorn J., Kaewpila N., Burns G.S., and Leong S. FAT, e-cadherin, beta catenin, Her-2/neu, Ki-67 immunoexpression, and histologic grade in intrahepatic cholangiocarcinoma. J Clin Pathol 58 (2005) 1249-1254
28. Kim H.J., Yoo T.W., Park D.I., et al. Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node positive patients. Ann Oncol 18 (2007) 892-897
29. Jorissen R.N., Walker F., Pouliot N., et al. Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 284 (2003) 31-53
30. Kari C., Chan T.O., Rocha de Quadros M., et al. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 63 (2003) 1-5
31. Marquez A., Wu R., Zhao J., et al. Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol 13 (2004) 1-8
32. Kearsley J.H., Leonard J.H., Walsh M.D., et al. A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas. Pathology 23 (1991) 189-194
33. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21 (2003) 3798-3807
34. Alvarez G., Perry A., Tan B.R., et al. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Path 19 (2006) 942-949
35. Buckley A.F., Burgart L., and Kakar S. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. Hum Pathol 37 (2006) 410-414
36. Buckley A.F., Burgart L., and Kakar S. Epidermal growth factor receptor and gene copy number in conventional hepatocellular carcinoma. Am J Clin Path 129 (2008) 245-251
37. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur J Cancer 37 (2001) S9-S15
38. Buckley A.F., and Kakar S. Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma. Appl Immunohistochem Mol Morphol 15 (2007) 305-309
39. Koo S.H., Ihm C.H., Kwon K.C., Park J.W., Kim J.M., and Kong G. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Genet Cytogenet 130 (2001) 22-28
40. Arteaga C.L. Epidermal growth factor receptor dependence in human tumors: more than just expression?. Oncologist 7 (2002) 31-39
41. Chung K.Y., Shia J., Kemeny N.E., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23 (2005) 1803-1810
42. Dei Tos A.P., and Ellis I. Assessing epidermal growth factor expression in tumors: what is the value of current test methods?. Eur J Cancer 41 (2005) 1383-1392
43. Moroni M., Veronese S., Benvenuti S., et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6 (2005) 279-286
44. Cappuzzo F., Hirsch F.R., Rossi E., et al. Epidermal growth factor receptor gene and protein and Gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
45. Cappuzzo F., Ligorio C., Jänne P.A., et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 25 (2007) 2248-2255
46. Yoshikawa D., Ojima H., Kokubu A., et al. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer 100 (2009) 1257-1266
47. Gwak G.Y., Yoon J.H., Shin C.M., et al. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol 131 (2005) 649-652
48. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England J Med 350 (2004) 2129-2139
49. Aishima S.I., Taguchi K.I., Sugimachi K., et al. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 40 (2002) 269-278
50. Terada T., Ashida K., Endo K., et al. c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. Histopathology 33 (1998) 325-331